Deep 6 AI Announces Release of Trial Recommender
Deep 6 AI announced the addition of Trial Recommender to its artificial intelligence (AI)-driven clinical trial acceleration platform. Trial Recommender lets physicians and their patients easily discover and participate in clinical research.
Leveraging the Deep 6 AI and NLP platform, Trial Recommender offers precision-matched clinical trial opportunities for patients, during their visit with a treating physician, based on real-time structured and unstructured clinical data.
Starting inside their EMR or the Trial Recommender portal, a physician can review precision-matched trial opportunities for their patients to determine study fit and impact. This empowers doctors to give their patients access to treatments and make data-driven decisions about their care. Trial Recommender also operates across the Deep 6 site network.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
